Venetoclax Combos Improve Progression-Free Survival in CLL

Venetoclax/obinutuzumab as well as a triple combo with ibrutinib demonstrated better PFS in fit patients with CLL vs chemo, but higher rates of serious adverse events with ibrutinib remain a concern. Medscape Medical News